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Background: Diagnostic and treatment approaches for sarcoidosis have changed dramatically over the past
decade. Yet, the most recent reports of trends in hospitalizations of sarcoidosis patients are over ten years old. The
objectives of this study were to determine the incidence of sarcoidosis among hospitalized patients and to analyze
recent trends and seasonality of hospitalizations in sarcoidosis patients.
Methods: We performed a retrospective cohort study of the Nationwide Inpatient Sample from 1998 through 2008.
We identified all hospitalizations with a primary or secondary diagnosis of sarcoidosis (ICD-9-CM code 135).
Incidence was modeled as a seasonal time series about a linear trend.
Results: Time series analysis of the monthly number of hospitalizations revealed a distinct positive linear trend.
Over the study period, the number of hospitalized patients with sarcoidosis increased from 37,516 to 70,947 cases.
Trends were most pronounced in patients older than 55 years (p< 0.0001), African Americans (p< 0.0001), females
(p = 0.0289), and non-Medicaid populations (p< 0.0001). Hospitalizations are seasonal with highest incidence in
January through March.
Conclusions: Hospitalizations among sarcoidosis patients have almost doubled during the past decade, with
disproportionate rate increases in African Americans, women, and older patients. The rate also increases among
patients with insurance other than Medicaid. This study indicates the need for heightened surveillance of
sarcoidosis patients given the unknown consequences of evolving treatment approaches. Our results point to a
need for research investigating risk factors for hospitalization, including medications, co-morbidities, demographics,
and socioeconomic status.
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Sarcoidosis is a systemic granulomatous inflammatory
disease of unknown etiology which can cause significant
morbidity [1,2]. It is characterized by the presence of
non-caseating granulomas, and although it can involve
almost any organ system, it primarily affects the lungs
[3]. Sarcoidosis affects all races, ages, genders, and ethni-
cities, but African Americans and women commonly
have more severe disease [3,4]. Sarcoidosis is not a* Correspondence: alicia-gerke@uiowa.edu
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reproduction in any medium, provided the orreportable disease in the United States (U.S.); therefore,
little is known about recent disease trends among
patients in the U.S.
Prior studies focusing on hospitalization trends among
patients with sarcoidosis report conflicting results. A study
of U.S. Navy personnel showed a steep decline in hospita-
lizations for sarcoidosis over the time period of 1975 to
2001, with the authors concluding that this was due to
improvements in protection from occupational exposures
that may have been causing sarcoidosis, or reflecting im-
provement in a ‘sarcoid-like’ disease from these exposures
[5]. However, a study using data from the national hospital
discharge survey from 1979–2000 demonstrated antd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cans had the highest frequency of hospitalization [6].
Since these studies were published, diagnostic and treat-
ment approaches have changed dramatically. More sensi-
tive imaging technologies to detect and monitor organ
involvement are now available, and increased use of im-
munosuppressive alternatives to prednisone (such as
methotrexate, leflunomide, azathioprine, and infliximab)
has altered clinical management over recent years [7-13].
Despite changing treatment and clinical strategies, there
are no published data reporting hospitalization trends and
outcomes in sarcoidosis patients over the past ten years in
the United States. This type of epidemiologic information
is important to assess the burden of this disease over time,
particularly in light of a recent study indicating that overall
mortality in sarcoidosis patients may be increasing [14].
The goal of this study was to determine the incidence
of sarcoidosis among hospitalized patients and to
analyze the recent trend in hospitalizations among
patients with sarcoidosis. We also examined demograph-
ics, hospital mortality, length of stay, and seasonal dis-
ease patterns.
Methods
All data were extracted from the Nationwide Inpatient Sam-
ple (NIS), the largest all-payer database of national hospital
discharges in the United States. The purpose of the NIS is
to specifically identify, track, and analyze national trends in
healthcare utilization, access, charges, quality, and out-
comes. It is maintained as part of the Healthcare Cost and
Utilization Project by the Agency for Healthcare Research
and Quality (AHRQ) and contains data from a 20 % strati-
fied sample of nonfederal acute hospitals [15]. This sample
includes academic medical centers, community hospitals,
general hospitals, and specialty hospitals. It excludes long-
term care facilities and rehabilitation hospitals. To adjust for
yearly changes in the sample, we applied the weights pro-
vided by the AHRQ [15]. The study investigators obtained
approval for use of this database from AHRQ/HCUP by
submission of a data use agreement. This is a de-identified
dataset and our IRB has determined that this study is not
human subjects research. We first identified all hospitaliza-
tions during the period from 1998 through 2008 during
which a primary or secondary diagnosis of sarcoidosis was
received. For case ascertainment, we used the International
Classification of Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) code 135. We then aggregated all cases of sar-
coidosis by month to produce a national sample of cases of
sarcoidosis over time. Cases of sarcoidosis were assigned to
a calendar month on the basis of the date that the patient
was admitted to the hospital. The numbers of sarcoidosis
cases were further converted to incidence rates to account
for the variation in total overall number of all hospitalized
discharges in each month.The yearly series for hospital mortality rate and aver-
age length of stay were also extracted to monitor the
characteristics of sarcoidosis patients over time. For each
year, the hospital mortality rate is defined as the number
of deaths during hospitalization over the total number of
sarcoidosis cases in that year.
We performed a time series analysis of the sarcoidosis
rate over the study period. Specifically, we built a sea-
sonal autoregressive integrated moving average (SAR-
IMA) model, which accounted for the serial correlation
and allowed us to test for a potential trend and for sea-
sonality in sarcoidosis incidence. After obtaining a suit-
able model for the national data, we then applied the
same model structure to each sub-series stratified by the
dichotomous variables age (< 55 vs. >= 55), race (black
vs. non-black), gender (female vs. male), and payer
(Medicaid vs. non-Medicaid). We chose 55 years old as
an age cut-off in order to capture the second bimodal
peak of presentation of sarcoidosis patients in their 60’s
that has been previously noted in epidemiological stud-
ies [3]. In a similar fashion, we conducted a time series
analysis of hospitalized patients with a primary diagnosis
of sarcoidosis based on all the scenarios described above.
To determine if there was a trend in hospital mortality
rate, we fit a logistic regression model with the year as the
independent variable. Generalized estimating equations were
used for parameter estimation and an autoregressive correl-
ation structure was incorporated to account for the temporal
association in the outcome. To investigate whether there
was a trend in average length of stay, we fit an analogous lin-
ear regression model, assuming normality for the distribu-
tion of the outcome.
All statistical analyses were performed using R version
2.11.1 (R Foundation for Statistical Computing) and SAS
9.2 (Cary, North Carolina, USA).
Results
Over the study period, the estimated number of hospitalized
patients with sarcoidosis almost doubled from 37,516 cases
in 1998 to 70,947 cases in 2008. Our time series analysis of
the sarcoidosis incidence rate revealed a significant upward
trend (Figure 1). Our final SARIMA model contained first-
order (p=0.0155) and second-order (p=0.0167) moving
average terms, a first-order seasonal (period of 12) moving
average term (p=0.0169), and an upward linear time trend
(p< 0.0001). Evidence of seasonality was provided by the
test result of the seasonal moving average component. Based
on the monthly distributions of the incidence rates from the
detrended series, it appeared that January, February, and
March were the peak months for sarcoidosis hospitaliza-
tions. The model showed no lack of fit based on the Dur-
bin-Watson test (p=0.4872) and an inspection of the
autocorrelation function (ACF) and partial ACF of the resi-
duals. The significant increase in the incidence rate was
Figure 1 Monthly incidence rates of hospitalizations among
patients with sarcoidosis (Nationwide Inpatient Sample,
1998–2008). The solid line represents the observed rate over time.
The dashed line is the fitted linear trend (p< 0.0001).
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and payer (Table 1).
The same model structure was applied to analyze the
monthly incidence rates due to primary diagnosis of sar-
coidosis. The second-order moving average did not appear
to be significant and thus was dropped from the model. The
seasonal moving average and linear time trend were
retained to provide statistical tests for potential seasonality
and trend. The first-order moving average (p=0.0467)
remained in the final model, but the first-order seasonal
moving average (p=0.3195) and linear time trend
(p=0.7259) were no longer significant (Figure 2), indicating
no observed seasonal variation or upward/downward trend
in incidence rates due to primary diagnosis of sarcoidosis.Table 1 Summary of linear trend tests for incidence rates of h
Inpatient Sample, 1998–2008)
Trend
Coef. Std. Err. P
Age: < 55 3.4783 0.3137 <
Age: >= 55 9.0293 0.2766 <
Race: Black 19.3509 1.4441 <
Race: Non-Black 4.2644 0.1652 <
Gender: Female 6.3568 0.3012 <
Gender: Male 5.5410 0.2208 <
Payer: Medicaid 1.7254 0.3425 <
Payer: Non-Medicaid 6.9836 0.2718 <
The linear time trend (monthly time index / 1000) is included in all models as a det
minus the slope in the second category.
* indicates significance at 0.05 level.Again, the model showed no lack of fit based on the Dur-
bin-Watson test (p=0.4973) and an inspection of the ACF
and partial ACF of the residuals. Similar results of linear
trend tests were observed in sub-series stratified by race,
gender, and payer (Table 2). However, for age we observed a
significant decrease in the incidence rate (p=0.0007) among
the younger population (i.e., age< 55).
We compared the slopes of linear trends between
different sub-series stratified by age, race, gender, and
payer. For the general sarcoidosis population (Table 1),
we observed larger slopes among the older (p< 0.0001),
black (p< 0.0001), female (p= 0.0289), and non-Medicaid
(p< 0.0001) sub-populations. For patients with a pri-
mary diagnosis of sarcoidosis, we also observed larger
slopes among the older (p< 0.0001), black (p= 0.1579),
female (p= 0.6824), and non-Medicaid (p= 0.1552) sub-
populations, although the difference in slopes is only
significant for the two sub-series stratified by age.
Over the study period, we found significant downward
trends in hospital mortality rate among both the general
sarcoidosis population (trend estimate =−0.0359, model-
based SE = 0.0080, p< 0.0001) and patients with a pri-
mary diagnosis of sarcoidosis (trend estimate =−0.0661,
model-based SE = 0.0168, p< 0.0001). A significant de-
crease in average length of stay was also observed for
general sarcoidosis population (trend estimate =−0.0482,
model-based SE = 0.0101, p< 0.0001), but not for
patients with a primary diagnosis of sarcoidosis (trend
estimate = 0.0110, model-based SE = 0.0132, p = 0.4047).Discussion
Our results show a dramatic increase in the number of
overall hospitalizations of sarcoidosis patients in the U.S.
between 1998 and 2008. We found the highest increase
in the rate of hospitalizations among African Americans,
females, older patients, and those with insurance otherospitalizations of patients with sarcoidosis (Nationwide
Difference
-Value Coef. Std. Err. P-Value
0.0001* −5.5510 0.4182 < 0.0001*
0.0001*
0.0001* 15.0865 1.4535 < 0.0001*
0.0001*
0.0001* 0.8158 0.3735 0.0289*
0.0001*
0.0001* −5.2582 0.4372 < 0.0001*
0.0001*
erministic covariate. The difference is defined by the slope in the first category
Figure 2 Monthly incidence rates of hospitalization due to a
primary diagnosis of sarcoidosis (Nationwide Inpatient Sample,
1998–2008). The solid line represents the observed rate over time.
The dashed line is the fitted linear trend (p = 0.7259).
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coidosis listed as the primary diagnosis, the incidence
was stable during the study period with no significant
differences in trends between races, gender, or insurance
status. Thus, it appears that this increasing trend is
driven by admissions for people with sarcoidosis, rather
than because of sarcoidosis.
Although sarcoidosis was first described over 100 years
ago, the cause is still unknown, treatment is still contro-
versial, and epidemiologic data are difficult to collect
due to the rarity of the disease and diverse clinical pre-
sentations. Our findings are important as there are few
published data on the burden of hospitalizations in thisTable 2 Summary of linear trend tests for incidence rates of h
(Nationwide Inpatient Sample, 1998–2008)
Trend
Coef. Std. Err. P
Age: < 55 −0.2604 0.0770
Age: >= 55 0.3830 0.0587 <
Race: Black 0.5696 0.3495
Race: Non-Black 0.0726 0.0412
Gender: Female 0.0423 0.0698
Gender: Male 0.0017 0.0705
Payer: Medicaid −0.1288 0.1105
Payer: Non-Medicaid 0.0488 0.0583
The linear time trend (monthly time index / 1000) is included in all models as a det
The difference is defined by the slope in the first category minus the slope in the s
* indicates significance at 0.05 level.disease in the past ten years. Our results clearly demon-
strate that there is an increasing burden of inpatient
medical care required by sarcoidosis patients, and that
this trend is greater in older patients, women, and Afri-
can Americans.
With respect to race, gender, and age, our results are
similar to those published by Foreman et al who
reported finding hospitalizations more frequently among
females, older patients, and African Americans [6]. Sar-
coidosis is generally more common in African Ameri-
cans and women [16-18]. Also, African Americans and
women tend to have more severe chronic disease and
extrapulmonary involvement [3,4]. Differences in ascer-
tainment and access to preventative and primary care
may also be playing a role in this case of disparity of out-
comes among African Americans [19]. Further, other
investigators have reported that socioeconomic status
plays a significant role in medical care and outcomes for
patients with sarcoidosis [4]. In previous studies of sar-
coidosis patients, less access to medical care has been
associated with depression, and lower family income and
lack of private or Medicare insurance is associated with
increased severity of disease [20,21].
In contrast to previous work, however, we found that
patients with insurance other than Medicaid actually had
a higher increase in the rate of hospitalization compared
to Medicaid patients. We speculate that this difference
may be due to differential practice patterns or access to
care/travel issues between patients with Medicaid and
those with alternative insurance. For instance, those with
insurance may be receiving more aggressive immunosup-
pression with corticosteroids, potentially more use of
costly immunosuppressive alternatives to prednisone (with
increased risky side effects), more diagnostic procedures,
or may be able to more easily access care (whether geo-
graphically or financially), thereby influencing treatmentospitalizations due to a primary diagnosis of sarcoidosis
Difference
-Value Coef. Std. Err. P-Value
0.0007* −0.6434 0.0968 < 0.0001*
0.0001*
0.1032 0.4970 0.3519 0.1579
0.0780
0.5445 0.0406 0.0992 0.6824
0.9808
0.2438 −0.1776 0.1249 0.1552
0.4026
erministic covariate.
econd category.
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radiographic imaging technology has also made it easier to
find potential sarcoidosis cases and identify more subtle
lung findings, which may have in turn led to more aggres-
sive treatment approaches than in times of monitoring
only with chest x-rays. Thus, the use of more sensitive
imaging in insured populations may contribute to more
aggressive immunosuppression.
Our hypothesis that the increase in hospitalizations is
associated with more aggressive immunosuppressive
treatments is further supported by the observation that
hospitalizations with a primary sarcoidosis diagnosis are
not increasing; increasing admission rates due to pri-
mary diagnoses other than sarcoidosis suggest that fac-
tors other than sarcoidosis itself are driving this trend.
In addition, a recent retrospective study of healthcare
utilization showed that sarcoidosis patients with greater
corticosteroid use had a greater number of unscheduled
emergency department visits [22]. Further support to
our hypothesis is provided by the increasing body of lit-
erature showing that the widespread introduction of
steroid-sparing immunosuppressive medications increases
hospitalizations from other diseases, especially inflamma-
tory bowel disease [23,24].
Because other studies have suggested a seasonal peak of
diagnosis of sarcoidosis cases in the early spring, we inves-
tigated the seasonality of hospital admissions among
patients with a sarcoidosis diagnosis [25,26]. Generally,
seasonality of a disease or outcome implies that the driv-
ing force is an environmental influence, such as a seasonal
viral infection or exposure. However, when we looked at
patients specifically admitted for a primary diagnosis of
sarcoidosis, we did not find any evidence of a seasonal
pattern. We did find a seasonal pattern (peaking in Janu-
ary, February, and March) for admissions due to all causes.
This could be associated with the timing of the influenza
season. However, influenza cannot account for the dra-
matic eleven-year overall increase in the rate of hospitali-
zations of sarcoidosis patients. We performed further
analyses to investigate whether the upward trend in sar-
coidosis over the study period is still statistically signifi-
cant after adjusting for influenza. This analysis was
performed on the overall series and on the subseries com-
prised of patients 55 and older (data not shown). Specific-
ally, we added a series representing national influenza
activity as an explanatory variable in our seasonal ARIMA
models for these series. In both models, the linear trend
remains highly statistically significant (both p-values
< 0.0001). Thus, adjustment for influenza does not impact
the trend in sarcoidosis admissions.
There are several limitations to our study. First, a major
limitation is that we use that we use administrative data,
and do not have access to laboratory, radiographic or medi-
cation data. Second, we cannot confirm our hypothesis thatimmunosuppressive drugs are driving the change in epi-
demiology, nor can the coded diagnosis of sarcoidosis be
confirmed. We also cannot report the burden of repeated
hospitalizations. Due to the sampling design in the AHRQ
database, there are no individual identifiers that can link
patients across multiple admissions or over multiple years.
Third, it is possible that medical advances are sustaining
patients for longer, leading to increased number of hospita-
lizations that are not necessarily related to the severity or
treatment of sarcoidosis. Fourth, it is also possible that sub-
groups with limited access to outpatient care (whether for
financial or geographic reasons) may be admitted more fre-
quently. Fifth, racial data in large databases may be missing
or inaccurate. Last, it is possible that the increase in hospi-
talizations is due to an increase in the prevalence of sar-
coidosis during the study period. However, hospitalizations
specifically for a primary diagnosis have remained stable,
suggesting that increased incidence of sarcoidosis is not the
driving factor for hospitalization. The incidence in popula-
tions in the United Kingdom and Australia (both with simi-
lar incidence data to the United States) show that the
diagnosis of sarcoidosis is not increasing over time [27,28].
Conclusion
This study highlights the need for heightened surveil-
lance of sarcoidosis patients, as the requirement for in-
patient care in this group is increasing. Our observations
are important given the unknown implications of evolv-
ing diagnostic and treatment approaches over this period
of time. Our results also point to a need for research in-
vestigating risk factors for hospitalization, including the
effects of medications, co-morbidities, demographics,
geographic patterns, socioeconomic status, and differing
practice patterns.
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